May 17, 2011 -- Paris --
New clinical data presented today at EuroPCR 2011 demonstrate
immediate
and long-term health-related quality-of-life (HRQoL) benefits
for patients receiving the Medtronic CoreValve® System from
Medtronic, Inc. (NYSE: MDT).
The favorable two-year results
from the 18-French
CoreValve multicenter prospective study are the largest set
of CoreValve HRQoL data and the longest-term HRQoL data available
from all transcatheter aortic valve implantation (TAVI) systems. |